Tag Archive for: ACI-7104

AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104

/in

All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement Discussions with FDA regarding future development path planned for early 2027 AC Immune to […]

Read more

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

/in

Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance Recent positive interim results showed safety and immunogenicity with early signals of activity Full week-100 results from Part 1 of VacSYn trial expected in H2 2026   Lausanne, Switzerland, August 11, 2026 – AC Immune SA (NASDAQ: ACIU), […]

Read more
© Optimum Strategic Communications.